An Exploratory, Open-label Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Cytoreductive Surgery

Trial Profile

An Exploratory, Open-label Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Cytoreductive Surgery

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs EC 1456 (Primary) ; Technetium Tc99m etarfolatide
  • Indications Ovarian cancer
  • Focus Pharmacodynamics
  • Sponsors Endocyte
  • Most Recent Events

    • 30 Mar 2018 Planned End Date changed from 1 Jun 2018 to 30 Apr 2018.
    • 30 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 02 Jun 2017 According to an Endocyte media release, the company plans to stop enrollment in EC1456 trials, where a careful assessment in folate receptor-positive (FR-positive) disease across multiple cohorts of patients and multiple dosing schedules did not yield the level of clinical activity necessary to support continued advancement of this agent. However, enrollment of a small number of patients in the this study will continue in order to inform other SMDC programs in development.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top